WATERTOWN, Mass., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Abata Therapeutics, a clinical-stage biotech company focused on transforming lives with Treg therapies for severe autoimmune and inflammatory ...
WATERTOWN, Mass., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Abata Therapeutics, a company focused on transforming lives with Treg therapies for severe autoimmune and inflammatory diseases, today announced ...
Abata Therapeutics has launched with $95 million in series A funding to take cell therapy into a new realm: the treatment of multiple sclerosis. The investment comes primarily from Third Rock Ventures ...
BOSTON--(BUSINESS WIRE)--Abata Therapeutics, a company focused on translating the biology of regulatory T cells (Tregs) into transformational medicines for patients living with severe autoimmune and ...
WATERTOWN, Mass.--(BUSINESS WIRE)--Abata Therapeutics, a company focused on translating the biology of regulatory T cells (Tregs) into transformational medicines for patients living with severe ...
(MENAFN- GlobeNewsWire - Nasdaq) First open IND for Abata's best-in-class autologous T cell receptor (TCR)-Treg cell therapy platform for autoimmune disease Expected initiation of first-in-human Phase ...
Abata Therapeutics Inc. announced it has received an equity investment from Bristol Myers Squibb to support the development of its Treg cell therapy products. Their investment supports Abata's ...
(MENAFN- GlobeNewsWire - Nasdaq) Dr. Beck's extensive experience in CMC and product development will be instrumental as Abata enters clinical development this year WATERTOWN, Mass., Sept. 16, 2024 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results